View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
References<br />
Viral dynamics during and after entecavir therapy 187<br />
1. Bortorelli F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F, et al. Long-term outcome<br />
of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood.<br />
Gastroenterol ogy 1990;99:805–810.<br />
2. Realdi G, Alberti A, Rugge M, Bortolotti F, Tigoli AM, Tremolada F, et al. Seroconversion from<br />
hepatitis B e antigen to anti HBe in chronic hepatitis B virus infection. Gastroenterology<br />
1980;79:195–199.<br />
3. Hoofnagle JH, Dusheiko GM, Seef LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion<br />
from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med<br />
1981;94:744–748.<br />
4. Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heath-cote J. Effect of alphainterferon<br />
treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a<br />
meta-analysis. Ann Intern Med 1993;119:312–323.<br />
5. Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, et al. The treatment<br />
effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables.<br />
Results based on individual patient data from 10 clinical controlled trials. European<br />
Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:646–655.<br />
6. Schiff E, Cianciara J, Karayalcin S, Kowdley K, Woessner M, McMullen S, et al. Durable HBeAg<br />
and HBsAg seroconversion after lamivudine for chronic hepatitis B (CHB) (abstract). J<br />
Hepatol 2000;2:99.<br />
7. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after<br />
lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology<br />
2000;32:803–806.<br />
8. Fontaine H, Driss F, Lagneau JL, Zylberberg H, Brechot C, Pol S. Hepatitis B virus reactivation<br />
after lamivudine discontinuation (abstract). Hepatology 1999;30(Suppl):349.<br />
9. Moraleda G, Spautelli J, Aldrich CE, Averett D, Condreay L, Mason W. Lack of effect of antiviral<br />
therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck<br />
hepatitis B virus. J Virol 1997;71:9392–9399.<br />
10. Delaney W, Miller T, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2<br />
system to study the effects of (-)-β-2’-3’-dideoxy-3’-thiacytidine on the replication of hepatitis<br />
B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chem<br />
1999;43:2017–2026.<br />
11. Innaimo SF, Seifer M, Bisacchi G, Standring D, Zahler R, Colonno RJ. Identification of BMS-<br />
200.475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chem<br />
1997;41:1444–1448.<br />
12. Yamanaka G, Wilson T, Innaimo S, Bisacchi G, Egli P, Rinehart JK, et al. Metabolic studies on<br />
BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents<br />
Chem 1999;43:190–193.